ACER - Acer Therapeutics GAAP EPS of -$0.31 misses by $0.30 revenue of $0.36M misses by $2.97M
Acer Therapeutics press release (NASDAQ:ACER): Q4 GAAP EPS of -$0.31 misses by $0.30. Revenue of $0.36M misses by $2.97M. Ended Q4 2021 with $12.7 million in cash and cash equivalents. Acer believes its cash and cash equivalents available as of December 31, 2021.
For further details see:
Acer Therapeutics GAAP EPS of -$0.31 misses by $0.30, revenue of $0.36M misses by $2.97M